Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

COVID-19 Risks & Treatment for Patients with Rheumatic Disease

Thomas R. Collins  |  December 4, 2020

ACR CONVERGENCE 2020—On March 12, a gastroenterologist tweeted about a registry that had been started to track outcomes for patients with gastrointestinal disorders who’d been diagnosed with COVID-19. A rheumatologist reposted it, asking whether such a registry had been started in rheumatology.

It hadn’t. But just two weeks later, the registry—now known as the Global Rheumatology Alliance registry—had been launched, and more than 20 cases were reported in the first 24 hours.

Dr. Grainger

Global Rheumatology Alliance
The quick action, said Rebecca Grainger, MBChB, PhD, associate professor of rheumatology at the University of Otago, New Zealand, in a talk at ACR Convergence, is a dramatic example of how the rheumatology community worldwide has come together during the pandemic.

Since then, data collected through the registry has helped point the way forward, identifying suitable treatment options and vulnerable populations, Dr. Grainger said. The Alliance, now a section of the ACR, includes data and support from approximately 300 professional and patient organizations, including the European League Against Rheumatism.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

From early data—about 600 cases from March and April—researchers found that being 65 years or older was associated with hospitalization from COVID-19, with an odds ratio (OR) of 2.55, as were hypertension, lung disease, diabetes and chronic kidney or end-stage renal disease (OR≈1.83–3.07). A daily prednisone dose of 10 mg or more per day was also associated with hospitalization (OR=2.12). Treatment with a biological or targeted synthetic disease-modifying anti-rheumatic drug (DMARD) was associated with a lower hospitalization risk (OR=0.46).

Researchers have also looked at disparities in outcomes, using U.S. data from about 1,300 cases from March to August. They’ve found that being Black (OR=2.8), Asian (OR=2.7) or Latinx (OR=1.7) is associated with higher risk of hospitalization. Being Latinx is also associated with a higher risk of requiring ventilation support (OR=3.3).

Based on about 3,300 cases from March to July, researchers found the risk of death from COVID-19 is associated with increased age, male sex, moderate to high rheumatic disease activity and, in the case of patients with rheumatoid arthritis (RA), ever having smoked.

Two studies based on Alliance data have already been published, with a third publication expected soon, Dr. Grainger noted.1,2

“As rheumatologists, we are in a strong position to advocate [for our patients],” she said. “We must advocate for measures that protect people with rheumatic disease, in particular people from racial and ethnic minorities. We must advocate for information, reduced infection risk” and more widespread testing.

Dr. Liew

Should DMARDs Be Stopped Preemptively?
In further discussion, Jean Liew, MD, MS, assistant professor of rheumatology at Boston University School of Medicine, described the hypothetical case of a 46-year-old man with stable RA, taking etanercept and methotrexate, who is concerned about COVID-19 exposure because he is a nurse in an outpatient clinic. Should he stop his medicines preventatively? If not, what if he gets exposed?

Overall, Dr. Liew said, the evidence suggests that conventional DMARDs should not be stopped preemptively, although some evidence from observational, registry-based data suggests sulfasalazine may be associated with higher odds of a poor outcome for someone who gets COVID-19.3,4 Not enough information for a hard conclusion exists, Dr. Liew said.

Regarding biologics and targeted small molecule drugs, the infection risk likely depends on the drug class. Tumor necrosis factor inhibitors have been found to be associated with lower odds of hospitalization.3 But is this a true protective effect?

“We cannot come to causal conclusions using these observational data,” Dr. Liew said. “We really need the results of ongoing trials.”

The picture surrounding Janus kinase inhibitors remains complicated: Baricitinib has been linked with a shorter time to recovery when used along with the antiviral remdesivir, compared with remdesivir alone, according to information on the ACTT-2 trial released by the manufacturer, although that phase 3 trial continues.5 Concern lingers about the effects on the interferon response and the infection risk, as well as the risk of thrombosis in those with COVID-19, she said.

Data collected through the registry has helped point the way forward, identifying suitable treatment options & vulnerable populations.

Big-picture messages, Dr. Liew said, are for patients with rheumatic and musculoskeletal diseases to continue their medications if their disease is under control and they do not have a COVID-19 diagnosis or exposure, and to use the lowest glucocorticoid dose possible.

For patients with exposure to SARS-CoV-2, patients should hold conventional DMARDs other than hydroxychloroquine and sulfasalazine, along with biologics, targeted synthetic drugs and other immunosuppressives, while they wait for test results. Patients diagnosed with COVID-19 should hold all medications other than hydroxychloroquine.

Those are the recommendations from the ACR COVID-19 Task Force, updated in July and based on the evidence available then.

Physicians should also remember that quarantine can contribute to higher disease activity and worse physical and mental health by decreasing activity levels and leading to sedentary behavior, Dr. Liew said.

“As clinicians, it’s important to recognize this and help patients adapt as well as possible.”


Thomas R. Collins is a freelance medical writer based in Florida. 

References

  1. Gianfrancesco MA, Leykina LA, Izadi Z, et al. Race/ethnicity  association with COVID-19 outcomes in rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance Physician Registry. Arthritis Rheumatol. 2020 Nov 3. Online ahead of print.
  2. Gianfrancesco MA, Hyrich KL, Al-Adely S, et al. Characteristics  associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020 Jul;79(7):859–866.
  3. Kilian, A, Chock YP, Huang IJ, et al. Acute  respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review. Semin Arthritis Rheum. 2020 Oct;50(5):1191–1201.
  4. Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids , but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: Results from an international registry. Gastroenterology. 2020 Aug;159(2):481–491.
  5. Eli Lilly & Company. News release: Baricitinib in combination with remdesivir reduces time to recovery in hospitalized patients with COVID-19 in NIAID-sponsored ACTT-2 trial. 2020 Sep 14.

Page: 1 2 3 | Multi-Page
Share: 

Filed under:ACR ConvergenceConditionsMeeting Reports Tagged with:ACR Convergence 2020COVID-19COVID-19 Global Rheumatology AllianceGlobal Rheumatology Alliance

Related Articles

    Rheumatology Online: Disseminating the State of the Art on Social Media at ACR Convergence 2022

    January 30, 2023

    PHILADELPHIA—A session on social media in rheumatology at ACR Convergence 2022 focused on how to use social media to promote one’s work and collaborate on international research projects, as well as the use of podcasts in educating rheumatologists. Engaging with Social Media at Conferences Dr. Liew Jean Liew, MD, MS, assistant professor of medicine in…

    Rheumatology Online: The State of the Art on Social Media

    February 9, 2023

    PHILADELPHIA—A session on social media in rheumatology at ACR Convergence 2022 focused on how to use social media to promote one’s work and collaborate on international research projects, as well as the use of podcasts in educating rheumatologists. Engaging at Conferences Dr. Liew Jean Liew, MD, MS, assistant professor of medicine in the Section of…

    The COVID-19 Global Rheumatology Alliance: Its Genesis, Development & Goals

    May 8, 2020

    Editor’s note: We are sad to announce that we have learned of the passing of Dr. Philip C. Robinson. We will share more as it becomes available, but in the meantime, we wanted to repost this article he wrote for The Rheumatologist early in the pandemic. Dr. Robinson also took the photo of the full-arc rainbow  below.

    The 2019 ACR Award Winners & Distinguished Fellows

    December 18, 2019

    ATLANTA—Every year at its Annual Meeting, the ACR recognizes its members’ outstanding contributions to the field of rheumatology through an awards program. The ACR is proud to announce 20 award recipients for 2019, honored for their accomplishments as clinicians, instructors or researchers who have helped advance rheumatology, for their commitment to inspire others to enter…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences